DEVELOPS A REVOLUTIONARY TOPICAL CREAM UTILIZING CANNABIS AND OPIOID MOLECULES FOR SAFER DELIVERY IN PATIENTS WITH CHRONIC PAIN AND ANXIETY
Delivra Corp. (DVA.V) has developed a revolutionary, proprietary topical cream base therapeutic, Delivra, for molecules of cannabis, cannabis-like and opioids, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety.
"Our goal is to develop innovative products using our proprietary topical delivery platform (Delivra) to meet significant unmet medical needs and improve quality of life. With our proven patent-pending technology and formulation expertise, we have created medical grade products that have shown significant efficacy and predictable outcomes to patients," said Dr. Joseph Gabriele, chief executive officer of Delivra. "With the capability to deliver products on the market immediately that provide superior efficacy with minimum side effects that are commercial ready, Delivra will capitalize on the significant growth opportunities ahead and advance innovative and alternative therapeutics to broaden the company's product offerings."
According to Health Canada Statistics, one in five Canadians from ages 12 to 44 suffer from chronic pain, representing a significant unmet medical need to improve treatments for patients. The Canadian Pain Society identifies chronic pain as an expensive problem, not only to the patient, but also society in general. The traditional treatments cost billions of dollars a year in health costs, lost productivity and social costs to lives that are further derailed by addiction or depression. According to National report by the federal government of Canada, the Canadian opioid related death rate is 8.8 per 100,000 population.
Delivra meets the growing need for specialized products with alternative delivery mechanisms for treating patients with less side effects than inhalation, needles and oral methods of drug delivery. Specifically, Food and Drug Administration-approved cannabis-like molecules such as nabilone, and a safer opioid molecule, buprenorphine, are combined and formulated with the company's patent-pending Delivra base; that have been successfully tested in human pain clinics and have demonstrated to help in numerous chronic pain patients to manage their symptoms. As a partner with the National Research Council of Canada, Delivra takes a strict regulatory approach by testing all formulations in the company's formulation laboratory and analytical facility including preclinical and clinical testing, to maximize the efficacy and benefits to the patient.
About Delivra Corp.
Delivra is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief brand, for conditions such as joint and muscle pain, nerve pain, varicose veins and wound healing, and under the LivSport brand for sports performance. LivRelief products are available in pharmacies, grocery chains and independent health food stores across Canada, and on-line at the LivRelief website. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally.